Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust, London, UK.
Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK.
BJOG. 2021 Jan;128(2):440-446. doi: 10.1111/1471-0528.16464. Epub 2020 Sep 14.
To evaluate the effectiveness of secondary screening using non-invasive prenatal testing (NIPT) in a routine NHS setting including test performance, turn-around times (TATs) and no-call (failure to obtain result) rates. To examine the influence of maternal and fetal characteristics on test performance.
Retrospective cohort.
London teaching hospital.
A total of 8651 pregnancies undergoing screening for fetal trisomy using NIPT provided by an NHS cell-free DNA screening laboratory - the SAFE laboratory.
Screening test evaluation and TATs. Univariate and multivariate logistic regression analysis to identify significant predictors of no-call results and reported by low fetal fraction (<2%), very high fetal fraction (>40%) and processing failure.
Test performance, TATs and no-call rates, factors affecting no-call results.
Average TAT was 4.0 days (95% CI 4.0-4.2 days). Test sensitivities for trisomies 21 and 13/18 were 98.9% (95% CI 95.9-99.9%) and 90.4% (95% CI 80.0-96.8%), respectively. The overall no-call rate was 32/8651 (0.37%, 95% CI 0.26-0.52%). The overall risk of a no-call result was influenced by gestational age, dichorionic twin pregnancy, history of malignancy and pregnancies affected by trisomy 13/18, but not by maternal weight or use of low-molecular-weight heparin.
High-throughput NIPT can be effectively embedded into a public health NHS setting. TATs of 4 days and no-calls of <0.5% were well within clinically desirable tolerances. Gestational age, maternal weight, assisted reproductive techniques, use of low-molecular-weight heparin and past history of malignancy did not have major impacts on test no-call rates and should not constitute reasons for withholding the option of NIPT from women.
Turn-around times of 4 days, no-call (test failure) rates of 0.37% and highly accurate NIPT can be successfully embedded in the NHS.
评估在常规国民保健制度(NHS)环境中使用非侵入性产前检测(NIPT)进行二级筛查的效果,包括检测性能、周转时间(TATs)和无呼叫(未能获得结果)率。研究产妇和胎儿特征对检测性能的影响。
回顾性队列研究。
伦敦教学医院。
共有 8651 例接受 NHS 游离 DNA 筛查实验室(即 SAFE 实验室)进行胎儿三体筛查的妊娠。
筛查试验评估和 TATs。使用单变量和多变量逻辑回归分析确定无呼叫结果的显著预测因素,并报告低胎儿分数(<2%)、非常高胎儿分数(>40%)和处理失败的报告。
检测性能、TATs 和无呼叫率,影响无呼叫结果的因素。
平均 TAT 为 4.0 天(95%CI 4.0-4.2 天)。21 三体和 13/18 三体的检测灵敏度分别为 98.9%(95%CI 95.9-99.9%)和 90.4%(95%CI 80.0-96.8%)。总的无呼叫率为 32/8651(0.37%,95%CI 0.26-0.52%)。总的无呼叫结果风险受胎龄、双胎妊娠、恶性肿瘤病史和 13/18 三体受影响的妊娠影响,但不受产妇体重或使用低分子肝素的影响。
高通量 NIPT 可以有效地嵌入公共卫生 NHS 环境中。4 天的 TAT 和<0.5%的无呼叫率在临床可接受的范围内。胎龄、产妇体重、辅助生殖技术、使用低分子肝素和恶性肿瘤病史对检测无呼叫率没有重大影响,不应该成为拒绝向妇女提供 NIPT 选择的理由。
4 天的周转时间、0.37%的无呼叫(检测失败)率和高度准确的 NIPT 可以成功地嵌入 NHS。